Lonza Group AG (FRA:LO3)

Market Cap	39.05B
Revenue (ttm)	7.59B
Net Income (ttm)	784.82M
Shares Out	n/a
EPS (ttm)	11.10
PE Ratio	49.75
Forward PE	28.35
Dividend	4.27 (0.77%)
Ex-Dividend Date	May 13, 2025

Volume	75
Average Volume	17
Open	556.60
Previous Close	561.80
Day's Range	555.80 - 556.60
52-Week Range	555.80 - 639.20
Beta	n/a
RSI	24.76
Earnings Date	Jul 23, 2025

About Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics; Small Molecules; Cell & Gene; and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substanc...

• Industry: Chemicals and Allied Products
• Founded: 1897
• Employees: 18,944
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: LO3

Financial Performance

In 2024, Lonza Group AG's revenue was 6.57 billion, a decrease of -2.13% compared to the previous year's 6.72 billion. Earnings were 636.00 million, a decrease of -2.75%.

Financial numbers in CHF